Travere Therapeutics (TVTX) Other Accumulated Expenses (2014 - 2026)

Travere Therapeutics (TVTX) has 13 years of Other Accumulated Expenses data on file, last reported at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 86.67% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (down 86.67% YoY), and the FY2025 full-year result was $3.2 million, down 81.33% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $2.1 million, down from $3.2 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $17.1 million in Q4 2024 and bottomed at $2.1 million in Q1 2026.
• The 5-year median for Other Accumulated Expenses is $5.4 million (2024), against an average of $7.0 million.
• The widest annual swing landed in 2024, when Other Accumulated Expenses jumped 226.64%; it then plunged 86.67% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $5.7 million in 2022, then decreased by 8.48% to $5.2 million in 2023, then surged by 226.64% to $17.1 million in 2024, then sank by 81.33% to $3.2 million in 2025, then tumbled by 34.25% to $2.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $2.1 million (Q1 2026), $3.2 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.

Peer Comparison